Home Cart Sign in  
Chemical Structure| 68572-87-2 Chemical Structure| 68572-87-2

Structure of 68572-87-2

Chemical Structure| 68572-87-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 68572-87-2 ]

CAS No. :68572-87-2
Formula : C14H11BO2
M.W : 222.05
SMILES Code : C1=CC=CC2=C1C=C(C3=CC=CC=C23)B(O)O
MDL No. :MFCD00143524
InChI Key :JCDAUYWOHOLVMH-UHFFFAOYSA-N
Pubchem ID :11775704

Safety of [ 68572-87-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 68572-87-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 17
Num. arom. heavy atoms 14
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 2.0
Molar Refractivity 71.28
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

40.46 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

3.33
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.67
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.26
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.39
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.73

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.86
Solubility 0.0308 mg/ml ; 0.000139 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.86
Solubility 0.0309 mg/ml ; 0.000139 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.65
Solubility 0.00501 mg/ml ; 0.0000225 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

Yes
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.29 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

2.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.98

Application In Synthesis of [ 68572-87-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 68572-87-2 ]

[ 68572-87-2 ] Synthesis Path-Downstream   1~5

  • 1
  • [ 21906-31-0 ]
  • [ 68572-87-2 ]
  • [ 1013933-56-6 ]
  • 2
  • [ 68572-87-2 ]
  • [ 171408-84-7 ]
  • [ 1333412-62-6 ]
  • 3
  • [ 68572-87-2 ]
  • [ 175205-81-9 ]
  • 2-(phenanthren-9-yl)-4-(trifluoromethyl)pyridine [ No CAS ]
YieldReaction ConditionsOperation in experiment
97.5% With tetrakis(triphenylphosphine) palladium(0); potassium carbonate; In tetrahydrofuran; water; at 80℃; for 24h;Inert atmosphere; General procedure: A mixture of phenanthren-9-ylboronic acid (1.00 g, 4.503 mmol), 2-bromo-4-methylpyridine (0.85 g, 4.954 mmol),tetrakis(triphenylphosphine)palladium (0.05 g, 0.045 mol, 1 molpercent), potassium carbonate(15 ml, 2M aqueous solution), and tetrahydrofuran (30 mL) was headed under a nitrogenatmosphere at 80°C for 24 h. This reaction is the Suzuki coupling reaction. After the reaction,the mixture was cooled to room temperature for 1 h. The compound was extracted byliquid-liquid separation (water and dichloromethane). The compound was purified by acelite-silica gel filtration (solvent: toluene) and column chromatography on silica gel (eluent:hexane/ethyl acetate, 15:1).
97.5% In 2-ethoxy-ethanol; at 130℃;Inert atmosphere; The PT-TFP ligand was synthesized as follows:phenanthren-9-ylboronic acid (1.00 g, 4.503 mmol) and<strong>[175205-81-9]2-bromo-4-(trifluoromethyl)pyridine</strong> (1.12 g, 4.954 mmol)were dissolved in 2-ethoxyethanol (67.20 ml) and refluxedovernight at 130 °C under nitrogen. After cooling to roomtemperature (?23 °C ) for 2 h, the compound was extractedby liquid?liquid separation (water-dichloromethane). Theafforded compound was purified, using toluene, by celitesilicagel filtration and column chromatography on silicagel, with a methanol/DMC mixture (1:20) as eluent. Theproduct was further purified by recrystallization. Yield:97.5percent (1.42 g); 1H NMR (500 MHz, CDCl3, delta (ppm):8.93 (d, J = 7.3 Hz, 2H), 8.44 (s, 1H), 8.38 (d, J =6.9 Hz, 1H), 8.12 (d, J = 7.1 Hz, 2H), 8.06 (s, 1H), 7.88(dd, J = 18.2 Hz, 2H), 7.82 (dd, J = 19.1 Hz, 2H), 7.15(d, J = 5.9 Hz, 1H).
89.3% Inert atmosphere; A PT-TFP ligand wasobtained from the reaction of <strong>[175205-81-9]2-bromo-4-(trifluoromethyl)pyridine</strong> (1.12 g, 4.95 mmol)and 9-phenanthrylboronic acid (1.00 g, 4.5 mmol) by Suzuki coupling. The abstraction and purification processes are the same as described above. Yield: 89.3percent (1.30 g); 1H NMR(CDCl3, 500 MHz): deltaH(ppm) 8.93(s, 2H), 8.44(s, 1H), 8.38(s, 1H), 8.12(s, 2H), 8.06(s,1H), 7.88(s, 2H), 7.82(s, 2H), 7.25(s, 1H)
  • 4
  • [ 52133-67-2 ]
  • [ 68572-87-2 ]
  • ethyl 2-(phenanthren-9-yl)-1H-pyrrole-3-carboxylate [ No CAS ]
  • 5
  • [ 68572-87-2 ]
  • [ 46258-62-2 ]
  • 1-(4-(phenanthren-9-yl)naphthalen-1-yl)ethanone [ No CAS ]
YieldReaction ConditionsOperation in experiment
79.2% With tetrakis(triphenylphosphine) palladium(0); potassium carbonate; In ethanol; water; toluene; for 5h;Reflux; 20 g (80.2 mmol) of <strong>[46258-62-2]1-acetyl-4-bromonaphthalene</strong> and 19.6 g (88.26 mmol) of 9-phenanthreneboronic acid were added to a 500 ml three-necked flask. After adding 33.3 g (240.87 mmol) of potassium carbonate and 2.78 g (2.4 mmol) of Pd (PPh3) 4, 150 ml of toluene, 75 ml of H2O,Ethanol (75 ml), and the mixture was refluxed for 5 hours while stirring.After completion of the reaction, the reaction mixture was extracted with MC. The organic layer was dried over MgSO4, purified by column chromatography, and crystallized with MeOH to obtain 22 g (79.2%) of Intermediate E.
 

Historical Records

Technical Information

Categories